Venetoclax with treosulfan before stem cell transplant

This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.

This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.

This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.

This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.

This trial tests whether adding venetoclax (a pill) to a lower-intensity bone marrow or stem cell transplant, and continuing it after transplant, helps prevent acute myeloid leukemia (AML) from coming back. You may join if you are in first remission and have a suitable donor.

This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.